BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
61.61
-1.12 (-1.79%)
Nov 7, 2025, 1:31 PM EST - Market open
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $120.70M in the quarter ending September 30, 2025, with 4,318.01% growth. This brings the company's revenue in the last twelve months to $353.78M, up 62.46% year-over-year. In the year 2024, BridgeBio Pharma had annual revenue of $221.90M with 2,285.27% growth.
Revenue (ttm)
$353.78M
Revenue Growth
+62.46%
P/S Ratio
33.78
Revenue / Employee
$484,630
Employees
730
Market Cap
11.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BBIO News
- 42 minutes ago - National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry - GlobeNewsWire
- 3 days ago - BridgeBio to Participate in November Investor Conferences - GlobeNewsWire
- 4 days ago - Biotech is back. Here's why these rallying stocks belong in your portfolio now. - Market Watch
- 4 days ago - BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025 - GlobeNewsWire
- 7 days ago - BridgeBio Pharma: Bullish On Attruby's Momentum And 2026 Catalysts - Seeking Alpha
- 8 days ago - BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 9 days ago - BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript - Seeking Alpha